Results 291 to 300 of about 277,075 (350)

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

open access: yesBMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan   +12 more
wiley   +1 more source

Reevaluating vitamin A for measles management in high-income settings. [PDF]

open access: yesLancet Reg Health Am
Suchdev PS, Krebs NF, Tanumihardjo SA.
europepmc   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

open access: yesBMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen   +7 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

open access: yesCancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae   +16 more
wiley   +1 more source

Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma

open access: yesCancer Communications, EarlyView.
Abstract Background Intrahepatic cholangiocarcinoma (ICC) is a challenging cancer with an increasing incidence. The Phase III TOPAZ‐1/KEYNOTE‐966 study demonstrated chemo‐immunotherapy (CIT) as a significant advancement, potentially replacing traditional chemotherapy for advanced biliary tract cancer.
Jinghan Zhu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy